Detection of SARS-Cov-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients

Demographic and clinical characteristics of the study population

One hundred and ninety-three patients were included; their main demographic and baseline clinical characteristics and laboratory findings are shown in Table 1 and S1 Table.

Depending on the technique, CoVemia was detected in 95 (48%; Roche) and 117 (59%; TFS) patients; the correlation between Ct (Cycle threshold) in serum obtained with both techniques was very good (r = 0.738 [0.667 − 0.795], p < 0.001), and detection by TFS was more sensitive than by Roche (S1A Figure). The agreement to detect CoVemia was 75.5% and the intraclass correlation coefficient was 0.612 (p < 0.001). Conversely, the correlation of Ct between nasopharyngeal and throat swab (NPTS) and serum samples was weak either with TFS or Roche techniques (S1B and 1C Figure, respectively).

• Download figure
• Open in new tab

S1 Figure:

Correlation between quantitative detection of SARS-CoV-2 in serum (CoVemia), either with Thermo Fisher Scientific (TFS) or Roche, and in nasopharyngeal and throat swab (NPTS). A) Correlation between CoVemia with TFS and Roche techniques; Correlation between SARS-CoV-2 detection in NPTS samples and Covemia using the TFS technique (B) or the Roche technique (C). Data are shown as dot plots of the mean Ct values of the RT-PCR for SARS-CoV-2 and the fitted linear prediction obtained with the option lfit of the command twoway of Stata. Correlation coefficients and significance levels were estimated with the Pearson’s test.

Patients with detectable CoVemia were older (p = 0.006), with worse baseline arterial oxygen tension/fraction of inspired oxygen ratio (PaO₂/FiO₂; p < 0.001), lower lymphocyte count (p < 0.001) and higher LDH (p < 0.001), IL-6 (p = 0.021), C-reactive protein (CRP; p = 0.022) and procalcitonin (p = 0.002) serum levels compared to patients without detectable CoVemia. In addition, they were more frequently treated with glucocorticoids (p = 0.016), either oral or bolus (p = 0.015), and with tocilizumab (p = 0.001) (Table 1 and S1 Table).

There were no significant differences in symptom duration at the time of sample collection between patients with and without CoVemia (9 days [95%CI: 4 – 13] and 8 [6 – 11] respectively; p = 0.223) with both techniques. Neither we observed correlation between disease duration and viral RNA detection in serum with both techniques (r = − 0.048 [-0.188 − 0.094], p = 0.510 for Roche, and r = −0.104 [-0.241 − 0.038], p = 0.151 for TFS).

Prevalence of SARS-CoV-2 viremia is higher in patients requiring ICU admission

In order to evaluate the relationship between COVID-19 severity and viremia we first studied the relative frequency of CoVemia in patients who required ICU admission and those who did not. As shown in Figure 1, viremia was significantly more frequent for both techniques in patients requiring ICU (p < 0.001 for Roche and p = 0.002 for TFS). Although TFS was more sensitive to detect CoVemia, it seemed to be less specific to predict the need for ICU (OR 2.47 [95% CI: 1.37 − 4.47], p = 0.003 for TFS vs 3.04 [1.71 − 5.44] p < 0.001 for Roche).

• Download figure
• Open in new tab

Fig. 1.

Detection of SARS-CoV-2 RNA in serum (CoVemia) is more frequent in patients requiring intensive care unit (ICU) admission. A) Roche technique. B) Thermo Fisher Scientific technique. Statistical significance was determined with the Chi squared test.

Additionally, we performed a multivariable logistic regression in order to determine whether CoVemia can help predicting ICU admission compared to other variables. The best model to predict the need for ICU admission included the following variables: COPD, total lymphocyte count and PaO₂/FiO₂ at admission (Table 2). When we forced CoVemia into this model, it did not reach statistical significance either when it was assessed by Roche or by TFS (Table 2).

In addition, when we specifically studied the 86 patients that required ICU admission, no association was found between the presence of CoVemia and the development of multiorgan dysfunction syndrome prior to admission and during the first 24 hours at the ICU (S2 Table).

SARS-CoV-2 viremia predicts mortality in COVID-19 admitted patients

As it was previously suggested that CoVemia can be associated with a higher risk of mortality, we also analyzed how both techniques predicted death during admission. TFS was more sensitive than Roche’s technique but less specific either in the whole population (OR 5.8 [2.6 − 13.3] for Roche and 3.3 [1.4 − 7.4] for TFS), or after stratification by requirement of ICU (S2 Figure).

• Download figure
• Open in new tab

S2 Figure.

Mortality is higher among patients with positive CoVemia, either in the whole population (left panels), in those patients requiring ICU admission (middle panels) or those no requiring ICU (right panels). Odds ratio (OR) and significance level for mortality according to the presence of CoVemia was estimated with the cs command of Stata. TFS: Thermo Fisher Scientific.

Therefore, we analyzed whether a threshold of CoVemia (as Ct) could help to better predict mortality during hospitalization. As shown in Figure 2A and 2B the area under ROC curves for Roche and TFS were quite similar (0.736 [0.642 − 0.829] vs 0.702 [0.603 − 0.801] respectively; p = 0.323). The best cut-off to predict mortality was 34 Ct for Roche (sensitivity 91%, specificity 38%) and 31 Ct for TFS (sensitivity 93%, specificity 32%). Using these cut-off points to define “relevant CoVemia”, the capability to predict mortality improved with both techniques: OR 9.2 (3.8 − 22.6) for Roche and 10.3 (3.6 − 29.3) for TFS (Figures 2C and 2D, respectively).

• Download figure
• Open in new tab

Fig. 2.

Comprehensive analysis of CoVemia as a prognostic marker of mortality in patients hospitalized for severe COVID-19. ROC curve-analysis for mortality prediction with Ct values in serum of all patients, according to Roche (A) and Thermo Fisher Scientific [TFS] (B) techniques. Proportion of deceased patients according to relevant CoVemia determined by Roche (C) and TFS (D) techniques. Survival analysis with Kaplan-Meier estimator of patients hospitalized for COVID-19 who presented (dotted lines) and patients who did not present (solid lines) relevant CoVemia according to Roche (E) and TFS (F) techniques.

In addition, Kaplan-Meier curves confirmed that those patients with “relevant CoVemia” at admission survived less than those with non-relevant detection of SARS-CoV-2 RNA (Figures 2E and 2F), being slightly higher the incidence risk ratio for CoVemia determined by TFS compared to Roche (IRR 4.1 [2.3 − 6.9] vs 2.4 [1.5 − 3.9] respectively).

SARS-CoV-2 viremia correlates with severity biomarkers previously described in COVID-19 patients

In order to further validate the usefulness of CoVemia as predictor of mortality in COVID-19, we analyzed its association with clinical and laboratory parameters that have been previously associated with worse outcomes [2,7,15]. As shown in Figure 3, higher levels of CoVemia were more frequent in elderly patients (p = 0.011) and correlated with higher qSOFA (p = 0.022), CURB65 (p = 0.014) and Charlson comorbidity (p = 0.078) indexes.

• Download figure
• Open in new tab

Fig. 3.

Association between CoVemia and main sociodemographic and clinical characteristics of patients hospitalized with severe COVID-19. Correlation between CoVemia levels (Ct value) and (A) age (years) and (B) Charlson comorbidity index (score). Distribution of CoVemia levels according to qSOFA index (C), and CURB65 scale (D) scores. All Ct data shown here were obtained by rRT-PCR in serum with Thermo Fisher Scientific (TFS) technique. In A and B panels data are shown as dot plots of the corresponding values and the fitted linear prediction (black line) obtained with the option lfit of the command twoway of Stata. Correlation coefficients and significance levels were estimated with the Pearson’s test. In C and D panels data are shown as box-plot representing the interquartile range (p75 upper edge, p25 lower edge, p50 midline in the box), p95 (line above the box), and p5 (line below the box). Significance level was determined with the Kruskall Wallis test.

Regarding laboratory parameters, CoVemia showed correlation with IL-6 serum levels and lymphocyte count (Figures 4A and 4B; p = 0.014 and p < 0.001, respectively), and a better correlation with lactate dehydrogenase serum levels (Figure 4C; p < 0.001). However, lower significant association was observed with ferritin and D-dimer levels (Figures 4D and 4E; p = 0.073 and p = 0.023, respectively).

• Download figure
• Open in new tab

Fig. 4.

CoVemia correlates with the main laboratory prognosis biomarkers described in patients hospitalized with severe COVID-19. Correlation between CoVemia levels (Ct value by Thermo Fisher Scientific [TFS] technique) and IL-6 levels (pg/mL) (A), lymphocytes count (cel/mm3) (B), LDH levels (U/L) (C), ferritin levels (ng/mL) (D), D-Dimer levels (mg/mL) (E). Data are shown as dot plots of the corresponding values and the fitted linear prediction (black line) obtained with the option lfit of the command twoway of Stata. Correlation coefficients and significance levels were estimated with the Pearson’s test.

Finally, we analyzed the hazard ratio for mortality of CoVemia in comparison with all these parameters. All models were adjusted by age and Charlson index, which significantly affected survival of COVID-19 patients, as well as by sex, which did not significantly affect survival. Baseline qSOFA and CURB65 showed the worst capability to predict survival (Table 3, model 1). On the contrary, the best predictors always included baseline “relevant CoVemia” and high LDH serum levels (Table 3, all models). Interestingly, even when relevant CoVemia, and high LDH levels were included together in model 4, both were able to independently predict survival, although the hazard ratio was higher for the former (Table 3 last two columns; HR 9.87 [4.13 − 23.57] for TFS CoVremia and 7.09 [3.39 − 14.82] for Roche CoVemia; HRs for high LDH 2.48 [1.21 − 5.09] with TFS CoVemia, and 2.39 [1.17 − 4.90] with Roche CoVemia).

Study design, population and data collection

This is a retrospective observational study of patients admitted to Hospital Universitario La Princesa (HUP) during the early weeks of the first wave of COVID-19 outbreak in Spain (Flow chart in S3 Figure).

• Download figure
• Open in new tab

S3 Figure:

Flowchart of patients included in the study.

Study inclusion criteria were: a) patients with confirmed detection of SARS-CoV-2 RNA in nasopharyngeal and throat swabs (NPTS), and b) availability of serum samples at the Microbiology Department for additional measurement of SARS-CoV-2 RNA in blood. Regarding the last criterion, on average, serum samples were obtained at a median of two days from admission (interquartile range [IQR] 1 to 3) which nearly corresponded to one week after the beginning of symptoms (median: 8 days, IQR: 6 to 11).

Clinical, laboratory and therapeutic data were collected from electronic clinical records and included in an anonymized database as previously described [6]. Baseline clinical data refer to those obtained at admission day and baseline laboratory data refer to one to three days from admission date.

SARS-CoV-2 RNA detection

Nasopharyngeal and throat swab samples were obtained and real-time reverse-transcription polymerase chain reaction (rRT-PCR) was performed with LightCycler^® Multiplex Virus Master (Roche Diagnostics, USA) using the LightMix^® Modular SARS and Wuhan CoV E-gene primers (Roche Diagnostics, USA), targeting the e gene as a first-line screening, followed by confirmatory testing with TaqPath™ COVID-19 CE-IVD Kit RT-PCR (Applied Biosystems™, USA) which detects three specific SARS-CoV-2 genomic regions: orf-1ab, s, and n genes. Both procedures were performed according to manufacturers’ directions on a Quant Studio-5 Real-Time PCR System (Applied Biosystems™, USA) and amplification curves were analyzed with QuantStudio™ Design and Analysis software (Applied Biosystems, USA), for their interpretation by a clinical microbiologist.

To evaluate CoVemia, we used 400 µL of surplus sera from routine HIV and hepatitis serology assessment that are usually frozen at −20 °C for internal quality controls. Serum samples were treated previously for virus inactivation and then tested with two rRT-PCR methods: cobas^® SARS-COV-2 test (Roche Diagnostics, USA), a qualitative assay for detection of SARS-CoV-2 RNA, and TaqPath™ COVID-19 CE-IVD RT-PCR Kit (Thermo Fisher Scientific [TFS], USA), a multiplex RT-PCR assay for qualitative detection of SARS-CoV-2 nucleic acids, as previously described [19]. The number of amplification cycles needed for the fluorescence signal to cross the threshold (Ct) was recorded. Briefly: a) Roche test detects a fragment of the orf-1ab region, specific of SARS-COV-2; and a conserved region of e gene, a structural envelope gene, for pan-sarbecovirus detection. Test was performed by cobas^® 6800 System (Roche Diagnostics, USA); an automatic platform for nucleic acid extraction and RT-PCR amplification and detection. Serum samples were processed according to manufacturer’s indications, following the same protocol used for SARS-CoV-2 detection in respiratory samples. Results were analyzed and interpreted automatically by the cobas^® 6800/8800 Software version 1.02.12.1002. B) TFS test detects three specific SARS-CoV-2 genomic regions: orf-1ab, s, and n genes. This technique requires a previous nucleic acid extraction from the sample, which was performed by the automatic eMAG^® Nucleic Acid Extraction System (Biomerieux, France), a validated system for the extraction of nucleic acids from serum and plasma samples. Extraction was carried out according to eMAG^® manufacturer’s directions, obtaining purified nucleic acids in 60 µL of elution buffer. Assay was performed using 5 µL of the eluted and according to the manufacturer’s instructions, by a QuantStudio™ 5 Real Time PCR System (Applied Biosystems, USA). Amplification curves were analyzed with QuantStudio™ Design and Analysis software version 2.4.3 (Applied Biosystems, USA). Interpretation of results was carried out by a clinical microbiologist, through amplification curve analysis.

IL-6 serum level measurement

IL-6 serum levels were quantified in duplicate with the Human IL-6 Quantikine high sensitivity enzyme-immune assay from R&D Systems Europe Ltd. (Abingdon, UK), as described previously [6].

Variables

We used two different variables to evaluate CoVemia: a) dichotomic variable: CoVemia was considered positive when at least one of the genes studied was positive according to the output of the two systems used; and b) quantitative variable: when more than one gene target was detected by one test, the mean Ct value of amplified genes was calculated. There was a high consistency among the results of the three genes analyzed with TFS and a slightly lower one for the two genes analyzed in the Roche system [19]. Since none of the two systems (Roche and TFS) provided positive results with Ct > 40, by consensus decision, we assigned Ct = 42 to those samples reported as negative (for all the genes) by the system.

Baseline IL-6 levels were considered high if > 30 pg/ml, according to their sensitivity and specificity to predict severity determined in a previous study [6]. In addition, in order to be able to compare different biomarkers, other continuous variables previously described as COVID-19 severity biomarkers were also transformed into dichotomic variables considering as cut-off point their median values in our population, namely: total lymphocyte count was considered low when < 700 cells/mm3, lactate dehydrogenase (LDH) serum level was considered high when > 400 U/L, qSOFA and CURB65 were considered high if > 1. Patients were considered elderly if age > 70 years.

Multiorgan dysfunction syndrome was considered when at least two organs reached a score > 1 in SOFA scale [23]. Multiorgan failure was considered when at least two organs reached a score > 3 in SOFA scale [24].

To analyze whether CoVemia could predict disease severity, two main outcomes were considered: need for ICU admission and all-cause in-hospital mortality. Only 14 patients out of 89 admitted to ICU did not require invasive mechanical ventilation.

Statistical analysis

Statistical analyses were performed using Stata 14 for Windows (Stata Corp LP, College Station, TX, USA). Quantitative variables following a non-normal distribution were represented as median and IQR, and the Mann Whitney test was used to assess significant differences. Variables with a normal distribution were described by mean ± standard deviation (SD) and differences between groups were assessed with Student’s t-test. Qualitative variables were described as counts and proportions and Chi square or Fisher’s exact test was used for comparisons. Correlation between quantitative variables was analyzed using the Pearson correlation test. To estimate the 95% confidence interval (CI) of correlation coefficients we used the ci2 command of Stata. To evaluate the agreement between CoVemia assessed by Roche and TFS we estimated the intraclass correlation with the icc command of R.

To determine the variables associated with the need for ICU admission, we performed a multivariable logistic regression analysis that was first modeled by adding all the variables with a p-value lower than 0.15 to the bivariable analysis, namely low lymphocyte count, D-dimer, high LDH, low PaO2/FiO2 (< 250), COPD, high qSOFA, high CURB65, hypertension, C-reactive protein, and high IL-6 level. The final model was reached through backward stepwise removal of variables with p-value higher than 0.15 and using Wald tests to demonstrate that each model was better than its previous iteration. Once the final model was obtained, the dichotomic variables CoVemia (both Roche and TFS) were forced into the model in order to determine whether they were able to predict the need for ICU admission.

Odds ratio (OR) for mortality according to the presence of CoVemia was estimated for both systems with the cs command of Stata. Since differences between the two techniques were detected in the sensitivity to detect viremia and the capability of predicting mortality, receiver operating characteristic (ROC) analyses were performed using the roctab command in order to estimate the best cut-off point for each system. Cut-off values for relevant CoVemia were selected based on the best trade-off values between sensitivity, specificity and the percentage of patients correctly classified. Survival time was analyzed by Kaplan-Meier method with the sts command of Stata. Date of admission was considered the date of entry, and for exit date we considered the date of death. For those patients without this event, the last revision of the database (electronic chart or telephone call) on May 21st was used to censor their follow-up. Differences in time to death between different variables were analyzed by log-rank test.

To compare the predictive capability of baseline CoVemia with that of other baseline parameters (qSOFA, CURB65, total lymphocyte count, LDH and IL-6 serum levels) described in previous publications [12,13,25] we fitted different Cox regression models. In the first model after adjustment by age, sex and Charlson comorbidity index, the hazard ratio (HR) for all other variables including relevant viremia by TFS or Roche was estimated. Since qSOFA and CURB65 did not reach a p-value < 0.15, they were excluded from the analysis in the subsequent models. Model 2 was adjusted by the same variables included in model 1 and low lymphocyte count, the hazard ratio for the remaining variables was then estimated. Model 3 and 4 were developed as model 2 but substituting low lymphocyte count by high IL-6 and high LDH, respectively.

Ethics

This study was approved by the local Research Ethics Committee (register number 4070) and it was carried out following the ethical principles established in the Declaration of Helsinki. All included patients (or their representatives) were informed about the study and gave an oral informed consent (registered in the electronic clinical chart) as proposed by AEMPS (Agencia Española de Medicamentos y Productos Sanitarios, The Spanish Agency for Medicines and Medical Devices) due to the COVID-19 emergency [26].

This article was written following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines taking into consideration the difficulties to obtain all needed information in the setting of the COVID-19 pandemic (S1 Appendix)